Trial · NCT00808067
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Major Bleeding, Annualized Rate of Subjects With Major Bleeds | Dabigatran 110 mg | 2.79 | percentage of subject-years | ||
| Major Bleeding, Annualized Rate of Subjects With Major Bleeds | Dabigatran 150 mg | 3.59 | percentage of subject-years | ||
| Stroke, Annualized Rate of Subjects With Stroke | Dabigatran 110 mg | 1.39 | percentage of subject-years | ||
| Stroke, Annualized Rate of Subjects With Stroke | Dabigatran 150 mg | 1.26 | percentage of subject-years | ||
| Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE | Dabigatran 110 mg | 0.25 | percentage of subject-years | ||
| Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE | Dabigatran 150 mg | 0.23 | percentage of subject-years | ||
| Pulmonary Embolism (PE), Annualized Rate of Subjects With PE | Dabigatran 110 mg | 0.10 | percentage of subject-years | ||
| Pulmonary Embolism (PE), Annualized Rate of Subjects With PE | Dabigatran 150 mg | 0.12 | percentage of subject-years | ||
| Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI | Dabigatran 110 mg | 0.72 | percentage of subject-years | ||
| Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI | Dabigatran 150 mg | 0.66 | percentage of subject-years | ||
| Deep Vein Thrombosis, Annualized Rate of Subjects With DVT | Dabigatran 110 mg | 0.06 | percentage of subject-years | ||
| Deep Vein Thrombosis, Annualized Rate of Subjects With DVT | Dabigatran 150 mg | 0.11 | percentage of subject-years | ||
| Death, Annualized Rate of Subject Death | Dabigatran 110 mg | 3.18 | percentage of subject-years | ||
| Death, Annualized Rate of Subject Death | Dabigatran 150 mg | 2.99 | percentage of subject-years | ||
| Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) | Dabigatran 110 mg | 1.60 | percentage of subject-years | ||
| Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) | Dabigatran 150 mg | 1.47 | percentage of subject-years | ||
| Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death | Dabigatran 110 mg | 4.40 | percentage of subject-years | ||
| Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death | Dabigatran 150 mg | 4.02 | percentage of subject-years | ||
| Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death | Dabigatran 110 mg | 3.51 | percentage of subject-years | ||
| Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death | Dabigatran 150 mg | 3.32 | percentage of subject-years |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00808067/results